Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 trial of VY-AADC01 in the patients with advanced Parkinson's disease

Trial Profile

Phase 2/3 trial of VY-AADC01 in the patients with advanced Parkinson's disease

Planning
Phase of Trial: Phase II/III

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs VY AADC (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Voyager Therapeutics
  • Most Recent Events

    • 29 Jan 2019 According to a Neurocrine Biosciences media release, the company entered into a strategic collaboration with Voyager Therapeutics. Under the terms of the agreement the company will fund the phase II/III pivotal program for VY-AADC.
    • 10 May 2018 According to a Voyager Therapeutics media release, Anticipated approval of IRB submissions along with feedback from a planned Type C meeting with the FDA, can allow for first patient dosing expected in the middle of this year.
    • 23 Jan 2018 According to a Voyager Therapeutics media release, the US FDA has cleared the Investigational New Drug (IND) application for VY-AADC.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top